The Second Canadian Symposium on hepatitis C virus: a call to action

In Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of those who undergo treatment will be approved. G...

Full description

Saved in:
Bibliographic Details
Published inCanadian journal of gastroenterology Vol. 27; no. 11; pp. 627 - 632
Main Authors Grebely, Jason, Bilodeau, Marc, Feld, Jordan J, Bruneau, Julie, Fischer, Benedikt, Raven, Jennifer F, Roberts, Eve, Choucha, Norma, Myers, Rob P, Sagan, Selena M, Wilson, Joyce A, Bialystok, Frank, Tyrrell, D Lorne, Houghton, Michael, Krajden, Mel
Format Journal Article Conference Proceeding
LanguageEnglish
Published Canada Hindawi Limited 01.11.2013
Pulsus Group Inc
Wiley
Subjects
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Canada - epidemiology
Conventions
Disease control
Epidemiology
Health Policy
Hepatitis
Hepatitis C - diagnosis
Hepatitis C - drug therapy
Hepatitis C - epidemiology
Humans
Mass Screening - methods
Medical screening
Public Health
Canada
Online AccessGet full text

Cover

More Information
Summary:In Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of those who undergo treatment will be approved. Given that most of those already infected are aging and at risk for progressive liver disease, building research-based interdisciplinary prevention, care and treatment capacity is an urgent priority. In an effort to increase the dissemination of knowledge in Canada in this rapidly advancing field, the National CIHR Research Training Program in Hepatitis C (NCRTP-HepC) established an annual interdisciplinary Canadian Symposium on Hepatitis C Virus. The first symposium was held in Montreal, Quebec, in 2012, and the second symposium was held in Victoria, British Columbia, in 2013. The current article presents highlights from the 2013 meeting. It summarizes recent advances in HCV research in Canada and internationally, and presents the consensus of the meeting participants that Canada would benefit from having its own national HCV strategy to identify critical gaps in policies and programs to more effectively address the challenges of expanding HCV screening and treatment.
Bibliography:ObjectType-Article-2
content type line 25
ObjectType-Conference-1
SourceType-Conference Papers & Proceedings-1
ISSN:0835-7900
2291-2789
1916-7237
2291-2797
DOI:10.1155/2013/242405